Generate Biomedicines, Inc. (GENB) stock
GENBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$10.38+0.54 (+5.49%)
Close on Nov 18, 2026Market cap $1.33BP/E –Yield –
Generate Biomedicines net income
Net income is the profit left for shareholders after every expense, interest and tax.
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$87.66M | – |
| Q2 FY2026 | Jun 30, 2026 | -$67.26M | – |
| Q1 FY2026 | Mar 31, 2026 | -$61.45M | – |
| Q3 FY2025 | Sep 30, 2025 | -$53.62M | – |
| Q2 FY2025 | Jun 30, 2025 | -$52.43M | – |
| Q1 FY2025 | Mar 31, 2025 | -$41.69M | – |
See a number that looks wrong?